Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Ipilimumab Combinations in Newly Diagnosed High Grade Glioma
NCT03425292Phase 1Completed
- Sponsor
- Providence Saint John's Cancer Institute
- Start
- Mar 2018
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in high-grade glioma (HGG) (6 arms), sponsored by Providence Saint John's Cancer Institute. Primary endpoint: Dose Limiting Toxicities at 28 days. Started Mar 2018; status: completed.
02
Drugs
03
Conditions
high-grade glioma (HGG)
Beyond the preview
Go deeper on NCT03425292.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03425292.